The Consensus Conference on Simultaneous Liver-Kidney Transplantation was a major policy-making event in the management of patients with HCV infection, cirrhosis, and end-stage renal disease. Its decisive contribution was to replace a simple diagnosis-based choice with a structured assessment of portal hypertension and hepatic reserve: selected patients with well-compensated cirrhosis might receive a kidney alone, while those with established or decompensated cirrhosis should be referred for consideration of combined liver-kidney transplantation.

Causes and Background

The conference arose from a difficult clinical boundary. HCV-infected kidney-transplant candidates may have advanced liver injury even when their cirrhosis appears clinically compensated; studies found stage 3 or 4 liver disease in 10–25% of candidates undergoing biopsy. Kidney transplantation in cirrhotic patients carries increased perioperative morbidity and mortality, greater susceptibility to infectious and metabolic complications, and poorer long-term survival, yet some patients are considered too healthy for liver transplantation and are consequently evaluated for kidney transplantation alone. The stakes were heightened by the broader consequences of HCV in renal replacement populations. Among dialysis patients, anti-HCV positivity was associated with increased all-cause mortality, with a pooled relative risk of 1.34 in a meta-analysis of 11,589 patients. Liver-related mortality was also substantially higher, and hepatocellular carcinoma and cirrhosis occurred more often among anti-HCV-positive patients. These outcomes made the choice of transplant strategy a question not only of surgical eligibility but also of how long-term liver disease would interact with renal replacement and immunosuppression.

Participants and Recommendation

The conference was co-sponsored by the American Society of Transplantation, the American Society of Transplant Surgeons, the American Society of Nephrology, and the United Network for Organ Sharing. Its central recommendation was to use portal-hypertension criteria in patients with well-compensated cirrhosis when deciding between simultaneous liver-kidney transplantation and kidney transplantation alone. The specific proposed threshold was a wedge hepatic vein pressure below 10 mm Hg for listing a patient for kidney transplantation alone. This criterion was explicitly presented as requiring validation in practice rather than as an unquestionable rule. Clinical programs described additional selection factors, including the absence of varices on endoscopy and a platelet count above 120 × 10^3/µl. Together, these measures treated portal hypertension as a practical indicator of whether the liver could tolerate kidney transplantation without simultaneous hepatic replacement.

Clinical Consequences

The conference did not eliminate uncertainty. Long-term post-transplant outcomes had not been definitively studied in HCV-infected kidney recipients with cirrhosis documented by pretransplant liver biopsy. In one single-center series, survival ten years after transplantation was only 26% among the small number of patients with pretransplant cirrhosis. Established or decompensated cirrhosis therefore remained a strong reason to involve a liver-transplant team and consider combined liver-kidney transplantation rather than proceeding with a kidney alone. The recommendation also reinforced the importance of staging liver disease before transplantation. Candidates should be screened for anti-HCV antibody and, where appropriate, active viremia by nucleic acid testing. For patients with active HCV infection, liver biopsy remained the reference method for identifying advanced fibrosis, because available noninvasive tests did not yet provide comparable accuracy and reliability. Patients on the kidney waiting list required regular monitoring for progressive liver disease, an especially important safeguard where waiting times could approach five to seven years.

Treatment and Allocation Context

The conference’s framework operated alongside a preference for treating HCV before kidney transplantation whenever possible. Interferon-based therapy after transplantation was associated with an increased risk of allograft rejection, and a meta-analysis of antiviral therapy in renal-transplant patients found an estimated sustained virologic response of only 18%, a dropout rate of 35%, and graft dysfunction as the most frequent reason for treatment interruption. For that reason, efforts to eradicate HCV were generally directed toward the pretransplant period. Pretransplant treatment nevertheless created a conflict with the use of kidneys from HCV-positive donors. Patients who achieved a sustained virologic response before transplantation were less likely to relapse after immunosuppression, but successful treatment also reduced the pool of HCV RNA-positive recipients eligible to receive an HCV-positive kidney. International recommendations consequently limited such organs to HCV RNA-positive candidates on the waiting list who had consented in advance. This was a calculated balance between transmission risk and the harm of prolonged dialysis: some patients could not tolerate, declined, failed, or could not afford antiviral treatment, and transplantation with an HCV-positive kidney might offer a more favorable course than remaining on dialysis.

Significance

The Consensus Conference on Simultaneous Liver-Kidney Transplantation made transplant eligibility a question of measurable physiological risk rather than a categorical consequence of an HCV diagnosis or a biopsy label alone. Its portal-pressure threshold, together with endoscopic and platelet criteria used by clinical programs, gave transplant teams a common language for distinguishing compensated disease that might permit kidney transplantation alone from hepatic disease requiring combined organ replacement. Its significance also lies in the tension it preserved rather than concealed. The decision had to weigh surgical risk, liver reserve, waiting-list time, treatment toxicity, rejection risk, infection, organ availability, and patient consent. By placing those competing harms within a formal recommendation while acknowledging that key thresholds still required validation, the conference linked clinical judgment to evidence without pretending that the evidence was complete.